evidence table

Selenium Thyroid Antibodies Randomized Trial Evidence Table

Name: Selenium Thyroid Antibodies Randomized Trial Evidence Table
Creator: Migaku
License: https://creativecommons.org/licenses/by/4.0/

Structured evidence table for Selenium Thyroid Antibodies Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topic	claim	evidence level	citation	source
Selenium Thyroid Antibodies Randomized Trial	Combination therapy significantly reduced TSH levels compared with Sel monotherapy (SMD -1.26; 95% CI -1.51 to -1.00; p 2 = 0%), and TSA suggested that this finding may be robust, although the evidence is limited by the small number of studies.	1	Stanchev P (2026)	Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto's Thyroiditis with Subclinical Hypothyroidism: A Systematic Review and Updated Meta-Analysis with Trial Sequential Analysis.
Selenium Thyroid Antibodies Randomized Trial	TgAb levels were also significantly reduced (SMD -0.51; 95% CI -0.78 to -0.24; p 2 = 0%); however, TSA indicated a potential risk of type I error.	1	Stanchev P (2026)	Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto's Thyroiditis with Subclinical Hypothyroidism: A Systematic Review and Updated Meta-Analysis with Trial Sequential Analysis.
Selenium Thyroid Antibodies Randomized Trial	Conclusions : MI combined with Sel was associated with a significant reduction in TSH levels compared with Sel alone in patients with HT and subclinical hypothyroidism, suggesting a potential therapeutic benefit.	1	Stanchev P (2026)	Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto's Thyroiditis with Subclinical Hypothyroidism: A Systematic Review and Updated Meta-Analysis with Trial Sequential Analysis.
Selenium Thyroid Antibodies Randomized Trial	Introduction : Hashimoto's thyroiditis (HT) is the leading cause of hypothyroidism in iodine-sufficient regions and often presents with subclinical hypothyroidism.	1	Stanchev P (2026)	Myo-Inositol Plus Selenium vs. Selenium Alone in Hashimoto's Thyroiditis with Subclinical Hypothyroidism: A Systematic Review and Updated Meta-Analysis with Trial Sequential Analysis.
Selenium Thyroid Antibodies Randomized Trial	Across studies, PBM was associated with reductions in thyroid autoantibodies, improvements in thyroid hormone indices, and decreases in LT4 dose requirements.	1	Berisha-Muharremi V (2026)	Photobiomodulation Therapy in Chronic Autoimmune Thyroiditis: A Systematic Review of Molecular Mechanisms and Clinical Applications.
Selenium Thyroid Antibodies Randomized Trial	However, current evidence is limited by the small number of human studies, heterogeneous PBM protocols, and the frequent use of concomitant interventions such as selenium or vitamin D.	1	Berisha-Muharremi V (2026)	Photobiomodulation Therapy in Chronic Autoimmune Thyroiditis: A Systematic Review of Molecular Mechanisms and Clinical Applications.
Selenium Thyroid Antibodies Randomized Trial	Chronic autoimmune thyroiditis (CAT), a common autoimmune thyroid disorder, is the leading cause of hypothyroidism in iodine-sufficient regions and is characterized by thyroid autoimmunity, chronic inflammation, and progressive structural thyroid changes.	1	Berisha-Muharremi V (2026)	Photobiomodulation Therapy in Chronic Autoimmune Thyroiditis: A Systematic Review of Molecular Mechanisms and Clinical Applications.
Selenium Thyroid Antibodies Randomized Trial	Although levothyroxine (LT4) restores biochemical euthyroidism, it does not directly address the underlying autoimmune process, highlighting the need for adjunctive therapeutic strategies.	1	Berisha-Muharremi V (2026)	Photobiomodulation Therapy in Chronic Autoimmune Thyroiditis: A Systematic Review of Molecular Mechanisms and Clinical Applications.